New drug could help people with short bowel syndrome ditch IV nutrition
NCT ID NCT03905707
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests the long-term safety of glepaglutide, a drug that mimics a natural gut hormone, in 145 adults with short bowel syndrome. The goal is to see if it can safely help the gut absorb more nutrients, potentially reducing the need for intravenous feeding. Participants must have completed a prior glepaglutide study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glepaglutide (a lab-made protein similar to GLP-2, which helps the gut absorb nutrients)
What this could lead to
If it works, this could reduce or eliminate the need for intravenous nutrition in people with short bowel syndrome, improving their quality of life.
What could go wrong
This is an extension trial focused on safety, not proof of effectiveness. The drug may cause side effects or not work for everyone. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT BOWEL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Kliniken Hamburg GmbH
Hamburg, Germany
-
Centre Hospitalier Lyon-Sud
Pierre-Bénite, France
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Hôpital Beaujon
Clichy, France
-
Mayo Clinic College of Medicine
Rochester, Minnesota, 55905, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Rigshospitalet
Copenhagen, Denmark
-
Solumed
Poznan, Poland
-
St Mark's Hospital
Harrow, United Kingdom
-
Szpital Skawina sp. z o.o. im. Stanley Dudricka
Skawina, Poland
-
The Royal Alexandra Hospital
Edmonton, Canada
-
UCLH Foundation NHS Trust
London, United Kingdom
-
UMC Radboud Nijmegen
Nijmegen, Netherlands
-
UZ Leuven
Leuven, Belgium
-
University Health Network - Toronto General Hospital
Toronto, Canada
-
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom
-
University of Chicago Children's Hospital
Chicago, Illinois, 60637, United States
-
University of East Anglia
Norwich, United Kingdom
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198-3285, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Universitätsklinikum Frankfurt - Med. Klinik I
Frankfurt, Germany
-
Universitätsmedizin Rostock
Rostock, Germany
-
Vanderbilt University Medical Center, Nashville
Nashville, Tennessee, 68198-3285, United States
-
Western University
London, N6A 4V2, Canada
-
Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
Lodz, Poland